Literature DB >> 12066961

Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population.

Huei-Xin Lou1, Michael A Shullo, Teresa P McKaveney.   

Abstract

STUDY
OBJECTIVE: To determine the long-term tolerability of prophylactic administration of pyrazinamide and levofloxacin in patients possibly exposed to multidrug-resistant tuberculosis (MDRTB) after undergoing solid organ transplantation.
DESIGN: Retrospective analysis.
SETTING: Community outpatient clinic. PATIENTS: Forty-eight recipients of solid organ transplants beginning prophylaxis for MDRTB during August 1999 after possible exposure to a single index case of multidrug-resistant Mycobacterium tuberculosis within our community INTERVENTION: Prophylaxis consisted of pyrazinamide 30 mg/kg/day plus levofloxacin 500 mg/day, administered for 1 year.
MEASUREMENTS AND MAIN RESULTS: Thirteen (27.1%) of the 48 patients completed therapy; 27 (56.3%) discontinued therapy within 4 months due to adverse drug events. Gastrointestinal intolerance was the major adverse event resulting in early discontinuation.
CONCLUSION: Prophylaxis of MDRTB with levofloxacin and pyrazinamide was associated with limited tolerability due to the high frequency of adverse events. While we search for a better tolerated prophylactic regimen, close monitoring for adverse reactions is recommended.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12066961     DOI: 10.1592/phco.22.9.701.34065

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  10 in total

1.  Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

Authors:  Eric Nuermberger; Sandeep Tyagi; Kathy N Williams; Ian Rosenthal; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2005-09-08       Impact factor: 21.405

Review 2.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

3.  Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.

Authors:  Tianyu Zhang; Si-Yang Li; Kathy N Williams; Koen Andries; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2011-06-09       Impact factor: 21.405

Review 4.  Tuberculosis of the central nervous system in immunocompromised patients: HIV infection and solid organ transplant recipients.

Authors:  Christina A Nelson; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2011-09-29       Impact factor: 9.079

5.  Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.

Authors:  Zahoor Ahmad; Sandeep Tyagi; Austin Minkowski; Charles A Peloquin; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2013-07-01       Impact factor: 21.405

Review 6.  Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.

Authors:  Suzanne M Marks; Sundari R Mase; Sapna Bamrah Morris
Journal:  Clin Infect Dis       Date:  2017-06-15       Impact factor: 9.079

7.  Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis.

Authors:  David P Holland; Gillian D Sanders; Carol D Hamilton; Jason E Stout
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

8.  Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure.

Authors:  Amyn A Malik; Mercedes C Becerra; Timothy L Lash; Lisa M Cranmer; Saad B Omer; Junaid Fuad; Sara Siddiqui; Farhana Amanullah; Maria Jaswal; Naseem Salahuddin; Salmaan Keshavjee; Hamidah Hussain; Neel R Gandhi
Journal:  Clin Infect Dis       Date:  2021-05-18       Impact factor: 20.999

Review 9.  Mycobacterial infections in solid organ transplant recipients.

Authors:  Harun Ur Rashid; Nura Afza Salma Begum; Tasnuva Sarah Kashem
Journal:  Korean J Transplant       Date:  2021-12-31

10.  Current management options for latent tuberculosis: a review.

Authors:  Brianna L Norton; David P Holland
Journal:  Infect Drug Resist       Date:  2012-11-29       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.